Lung Cancer Perspective

• The Case for Post-COVID Steroids   Dr F. Perry Wilson cautions against changing practice on the basis of a single study.
  Medscape, May 12, 2022
• ATS 2022 Read clinically focused news coverage of key developments from ATS 2022
  Medscape Pulmonary Medicine, May 10, 2022
• Finding Your Wolfpack in Academic Medicine How I learned to surround myself with like-minded people in academic medicine to no longer feel "out of place."
  Medscape Blogs, May 10, 2022
• Double Trouble: Lung Cancer and Coexisting COPD: The Future of Care   Experts discuss the future of care for lung cancer patients and examine the possibility of managing lung cancer as a chronic disease.
  Medscape TV, May 03, 2022
• A Year of Lung Cancer Improvements, With More Work To Do   Dr Mark Kris discusses good news in lung cancer and urges efforts to improve lung cancer screening.
  Medscape Oncology, April 21, 2022
• Oncogene-Positive Lung Cancer: What Therapy to Start?   Dr Mark Kris discusses the choice between chemotherapy and targeted therapy in patients with lung cancer and oncogenic drivers.
  Medscape Oncology, April 20, 2022
• Twitter Polls: Tapping Into the Wisdom of Crowds Oncologist Jack West explores the powerful benefits of Twitter polls.
  Medscape Oncology, April 14, 2022
• Double Trouble: Lung Cancer and Coexisting COPD: A Multidisciplinary Approach   Doctors discuss the importance of a multidisciplinary approach when treating patients with COPD and lung cancer.
  Medscape TV, March 30, 2022
• NSCLC e-Tumor Boards: Case 3: ALK-Rearranged NSCLC with Brain Metastasis   The third case focuses on a 65-year-old woman with ALK-rearranged non-small-cell lung cancer, who had a history of prior stereotactic radiosurgery to a left parietal periventricular metastasis. The Brain Metastasis team discusses treatment management and surgery options.
  Medscape, March 25, 2022
• We're Finally Beginning to Crack the KRAS Nut in Colorectal Cancer   After 30 years, we may at last have drugs to treat KRAS G12C-mutant colorectal cancer.
  Medscape Oncology, March 08, 2022
• Is a PFS Benefit Alone Really Worth $10,000 a Month? Oncologist H. Jack West explores whether and when to consider surrogate endpoints to be practice-changing.
  Medscape Oncology, March 02, 2022
• Rapid Recommendation Update From ASCO for Stage IB-IIIA NSCLC   The new recommendations include adjuvant osimertinib and atezolizumab, which can cure certain patients with stage IB to IIIA NSCLC.
  Medscape Oncology, February 08, 2022
• The Illustrious Patient — Diseases of Famous People The lives of prominent figures in history were shaped by various diseases.
  Medscape Features Slideshows, February 07, 2022
• Alleviating Chemo-Related Nausea Is a Huge Unmet Need   We need to do more to address our patients' most concerning adverse effect, says Dr Mark Kris.
  Medscape Oncology, February 02, 2022
• ESMO 2020 ctDNA Shows Promise for Assessing Lung Cancer Treatment Response   Dr Mark Kris predicts that tumor-informed assays will soon become the standard of care.
  Medscape Oncology, January 27, 2022
• Double Trouble: Lung Cancer and Coexisting COPD: Direct Target   Doctors discuss treatment strategies in NSCLC patients who are candidates for targeted therapy but who have comorbid COPD.
  Medscape TV, January 26, 2022
• Swinging for the Fences: Curing NSCLC Oncologist Jack West explores the major advances we've made in treating NSCLC and makes predictions for what's to come in the curative setting.
  Medscape Oncology, January 20, 2022
• Top 5 Developments in Lung Cancer in 2021   Advances in gene targets and their treatments dominated the therapeutic landscape for 2021, says Dr Mark Kris.
  Medscape Oncology, January 04, 2022
• Pembrolizumab +/- Chemotherapy: Reading Between the Studies   Dr Mark Kris discusses how to read between the studies to determine optimal treatments for patients when clinical trial data are not available.
  Medscape Oncology, December 30, 2021
• Early Data Support Neoadjuvant Immunotherapy for NSCLC   A handful of studies on neoadjuvant immunotherapy for lung cancer are nearing completion, Mark Kris reports.
  Medscape Oncology, December 22, 2021